Rec'd PCT/PTO 2 9 APR 2002

Group Art Unit: Unassigned

Examiner: Unassigned

PATENT Attorney Docket No. 213673

IN THE CONTROL STATES PATENT AND TRADEMARK OFFICE

In re Application of:

בוובט

BEAUCAGE et al.

Application No. 09/937,292

Filing Date: September 24, 2001

For: N-ACYLPHOSPHORAMIDITES AND

THEIR USE IN OLIGONUCLEOTIDE

APR 2 9 2002

**SYNTHESIS** 

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Pursuant to 37 CFR 1.97 and 1.98, the references listed on the enclosed Form PTO-1449 and/or Substitute Form PTO-1449 ("Form 1449") are submitted for consideration by the Examiner in the examination of the above-identified patent application.

The full consideration of the references in their entirety by the Examiner is respectfully requested and encouraged. Also, it is respectfully requested that the references be entered into the record of the present application and that the Examiner place his or her initials in the appropriate area on the enclosed Form 1449, thereby indicating the Examiner's consideration of each of the references.

The submission of the references listed on the Form 1449 is for the purpose of providing a complete record and is not a concession that the references listed thereon are prior art to the invention claimed in the patent application. The right is expressly reserved to establish an invention date earlier than the above-identified filing date in order to remove any reference submitted herewith as prior art should it be deemed appropriate to do so.

Further, the submission of the references is not to be taken as a concession that any reference represents art that is relevant or analogous to the claimed invention. Accordingly, the right to argue that any reference is not properly within the scope of prior art relevant to an examination of the claims in the above-identified application is also expressly reserved.

## **CERTIFICATE OF MAILING**

I hereby certify that this INFORMATION DISCLOSURE STATEMENT (along with any documents referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231.

April 24, 2002

Peter Pailips



In re Appln. of BEAUCAGE et al. Application No. 09/937,292

The Information Disclosure Statement is being filed:

$\boxtimes$	within any one of the following time periods: (a) within three months of the filing date of a national application other than a continued prosecution application under 37 CFR 1.53(d); (b) within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 of an international application; (c) before the mailing date
	of a first Office Action on the merits; or (d) before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.
	after (a), (b), (c) or (d) above, but before the mailing date of a final action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an action that otherwise closes prosecution in the application, and includes <i>one</i> of:
	the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below).  or
	the fee of \$180 set forth in 37 CFR 1.17(p) (see "Fees" below).
	after the mailing date of a final action under 37 CFR 1.113 or a Notice of Allowance under 37 CFR 1.311, or an action that otherwise closes prosecution in the application, and on or before payment of the issue fee, and includes the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below), and the fee of \$180 as set forth in 37 CFR 1.17(p) (see "Fees" below).
	after the mailing date of a Notice of Allowance under 37 CFR 1.311, and on or before payment of the issue fee, and within thirty days of receiving each item of information contained in the Information Disclosure Statement, and includes the Statement under 37 CFR 1.704(d) (see "Statement under 37 CFR 1.704(d)" below), and the fee of \$180 as set forth in 37 CFR 1.17(p) (see "Fees" below).  NOTE: This is for original applications except applications for a design patent, filed on or after May 29, 2000, wherein a paper containing only an Information Disclosure Statement in compliance with 37 CFR 1.97 and 1.98 is being filed.
Coj	pies of the References
	Copies of the references listed on the enclosed Form 1449 are enclosed herewith. Attached to each reference not in the English language is a concise explanation of the relevance pursuant to 37 CFR 1.98(a)(3). An English-language equivalent/ patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of the relevance pursuant to 37 CFR 1.98(a)(3).
	A copy of the foreign search report is enclosed herewith

	In re Applin. of BEAUCAGE et al. App! ation No. 09/937,292								
The references listed on the enclosed Form 1449 were previously identified in the parent application(s) of the present application, and copies of the references were furnished at that time. Accordingly, additional copies of the references are not submitted herewith, so as not to burden the file with duplicate copies of references. The Examiner is respectfully requested to carefully review the references in accordance with the requirements set out in the Manual of Patent Examining Procedure. In accordance with 37 CFR 1.98(d), the details of the parent application(s) relied upon for an earlier filing date under 35 USC 120 in which copies of the references were previously furnished are set out below:									
	U.S. APPLIC	CATIONS	ST	ATUS (CHECK C	NE)				
	U.S. APPLICATIONS	U.S. FILING DATE	PATENTED	PENDING	ABANDONED				
1.	0 /								
2.	0 /								
3.									
٦.									
<ul> <li>□ The undersigned hereby states that each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.</li> <li>□ The undersigned hereby states that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.</li> </ul>									
Sta	tement under 37 CF	R 1.704(d)							
	The undersigned hereby states that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 CFR 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.								
Fee	s								
	No fee is owed by the	e applicant(s).  Ounder 37 CFR 1.17(p)	is enclosed he	rewith					

In re Appln. of BEAUCAGE et al. Application No. 09/937,292

Method	of P	ayment	of	Fees
--------	------	--------	----	------

	•
	Atterned is a check in the amount of \$ .  Charge Deposit Account No. 12-1216 in the amount of \$ . (A duplicate copy of this communication is enclosed for that purpose.)
Aut	thorization to Charge Additional Fees
$\boxtimes$	If any additional fees are owed in connection with this communication, please charge Deposit Account No. 12-1216. (A duplicate copy of this communication is enclosed for that purpose.)
Ins	tructions as to Overpayment
$\boxtimes$	Credit Account No. 12-1216. Refund
	*

Respectfully submitted,

Kenneth P. Spina, Registration No. 43,927 LEYDIG, VOIT & MAYER, LTD.

Two Prudential Plaza, Suite 4900

180 North Stetson

Chicago, Illinois 60601-6780

(312) 616-5600 (telephone)

(312) 616-5700 (facsimile)

Date: April 24, 2002

Please type a plus sign (+) inside this box

PTO/SB/08A/B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

			5,18		Complete if Known
	form 1449A/B/PTO	APR	2 9 2002	Application Number	09/937,292
INF	ORMATION	DIS	CLOSERE	Filing Date	September 24, 2001
STA	TEMENT BY	<b>KAI</b>	ZRAKĆĂNT	First Named Inventor	BEAUCAGE, Serge L.
				Group Art Unit	
	(Use as many sheet	s as ne	ecessary)	Examiner Name	
Sheet	1	of	5	Attorney Docket Number	213673
· ·					

			-	U.S. PATENT DOCUM	MENTS	*		
Examiner	Cite	U.S. Patent Docum	Kind	Name of Patentee or Applicant of	Date of Publication of Cited			Filing Date If
Initials1	No.	Patent Number	Code	Cited Document	Document MM-DD-YYYY	Class	Subclass	Appropriate
	AA	3,534,017		Fujimoto et al.	10-13-1970 .			
	AB	4,415,732		Caruthers et al.	11-15-1983			
	AC	4,417,046		Hsiung et al.	11-22-1983			
	AD	4,458,066		Caruthers et al.	07-03-1984			-
	AE	4,663,446	:	Wright	05-05-1987			
	AF	4,668,777		Caruthers et al.	05-26-1987			
	AG	4,725,677		Köster et al.	02-16-1988			
	АН	4,739,044		Stabinsky	04-19-1988			
	ΑI	4,757,141		Fung et al.	07-12-1988			-
	AJ	4,808,708		Yoshida et al.	02-28-1989			
	AK	4,816,569		Miyoshi	03-28-1989			
-	AL	4,816,570		Farquhar	03-28-1989			
0	AM	4,845,205		Huynh Dinh et al.	07-04-1989			
	AN	4,849,513		Smith et al.	07-18-1989			
	AO	4,973,679		Caruthers et al.	11-27-1990			
	AP	4,980,460		Molko et al.	12-25-1990			
	AQ	5,026,838	1-7	Nojiri et al.	06-25-1991			
	AR	5,039,796		Engels et al.	08-13-1991			
	AS	5,071,974		Groody	12-10-1991	*		

A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

Examiner Signature		Date Considered		
-----------------------	--	--------------------	--	--

<sup>+</sup> An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

<sup>&</sup>lt;sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/B/PTO

## INFORMATION DESCLOSURESTATEMENT BY APPLICANT

(Use as many sheets as necessary)

 Sheet
 2
 of
 5

	Complete if Known		
Application Number	09/937,292		
Filing Date	September 24, 2001		
First Named Inventor	BEAUCAGE, Serge L.		
Group Art Unit			
Examiner Name		-	
Attorney Docket Number	213763		

U.S. PATENT DOCUMENTS								
Examiner	Cite	U.S. Patent Docum	ent Kind	Name of Patentee or Applicant of	Date of Publication of Cited			Filing Date If
Initials <sup>1</sup>	No.	Patent Number	Code	Cited Document	Document MM-DD-YYYY	Class	Subclass	Appropriate
:	AT	5,091,519		Cruickshank	02-25-1992			
	AU	5,134,228		Takaku	07-28-1992	•		-
	AV	Re.34,069		Köster et al.	09-15-1992			
·	AW	5,166,330		Engels et al.	11-24-1992			
	AX	5,212,304		Fung et al.	05-18-1993			
	AY	5,214,135		Srivastava et al.	05-25-1993	-		
	ΑZ	5,252,760		Urdea et al.	10-12-1993			
	ВА	5,258,538		Fung et al.	11-02-1993			
	ВВ	5,324,831		Marquez et al.	06-28-1994			
	ВС	5,332,845		Urdea et al.	07-26-1994	•		
,	BD	5,348,868		Reddy et al.	09-20-1994			
	BE	5,428,148		Reddy et al.	06-27-1995			
	BF	5,430,138		Urdea et al.	07-04-1995			À.,
	BG	5,449,602		Royer et al.	09-12-1995			
	вн	5,506,351		McGee	04-09-1996			
	BI	5,510,476		Ravikumar et al.	04-23-1996			
	BJ	5,518,651		Reddy et al.	05-21-1996	, = Y		
	ВК	5,525,719		Srivastava et al.	06-11-1996			
	BL	5,556,961		Foote et al.	09-17-1996			
	ВМ	5,571,902		Ravikumar et al.	11-05-1996			

A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

Examiner Signature	Date Considered	
-----------------------	--------------------	--

<sup>+</sup> An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

<sup>&</sup>lt;sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Complete if Known

Substitute for form 1449A/B/PTO	P	APR	2	9 2002	/بير
INFORMATION DI STATEMENT BY	•	A .	); (图)	SUR DAN	E/ T

Application Number 09/937,292

Filing Date September 24, 2001

First Named Inventor BEAUCAGE, Serge L.

Group Art Unit

(Use as many sheets as necessary)

Sheet 3 of 5

Attorney Docket Number 213763

**Examiner Name** 

	U.S. PATENT DOCUMENTS								
Examiner Initials¹	Cite No.	U.S. Patent Docume Patent Number	nt Kind Code	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Class	Subclass	Filing Date If Appropriate	
	BN	5,574,146		Reddy et al.	11-12-1996				
	во	5,614,622		Iyer et al.	03-25-1997				
	ВР	5,616,700		Reddy et al.	04-01-1997	····			
	BQ	5,623,068		Reddy et al.	04-22-1997			<del></del>	
	BR	5,645,985		Froehler et al.	07-08-1997			-	
	BS	5,646,265		McGee	07-08-1997				
	BT	5,681,940	<u></u>	Wang et al.	10-28-1997				
	BU	5,700,919		Seliger et al.	12-23-1997			<del></del>	
	BV	5,703,223		Wickstrom et al.	12-30-1997				
_	BW	5,705,621		Ravikumar	01-06-1998				
	ВХ	5,712,378		Wang	01-27-1998				
	ВҮ	5,714,597		Ravikumar et al.	02-03-1998				
-	BZ	5,731,429		Reddy et al.	03-24-1998				
	CA	5,959,099		Cheruvallath et al.	09-28-1999				

					FOREIGN PATENT DOCUMENT	S				
		Fo	reign Patent Docume	ent					Trans	lation
Examiner Initials <sup>1</sup>	Cite No.	Office	Number	Kind Code	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Class	Subclass	Yes	No*
	СВ	EP	0006220	A	Hoechst AG	01-09-1980			X <sup>+</sup>	
	СС	EP	0090789	A	Monsanto Company	10-05-1983				•
	CD	EP	0196101	A	Chiron Corporation	10-01-1986				

<sup>\*</sup> A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

Examiner Date Considered Considered
-------------------------------------

<sup>+</sup> An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

<sup>&</sup>lt;sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

APR 2 9 2002

Substitute for form 1449A/B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 4 of 5

	Complete if Known	
Application Number	09/937,292	
Filing Date	September 24, 2001	
First Named Inventor	BEAUCAGE, Serge L.	
Group Art Unit		
Examiner Name		
Attorney Docket Number	213763	

					FOREIGN PATENT DOCUMENT	S				
Examiner Initials¹		Fo	reign Patent Docume							lation
	Cite No.	Office	Number	Kind Code	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Class	Subclass	Yes	No*
	CE	EP	0219342	Α	Genentech, Inc.	04-22-1987				
	CF	EP	0241363	A	Commissariat a L'Energie Atomique (Paris)	10-14-1987			X <sup>+</sup>	
	CG	EP	0323152	A	Applied Biosystems, Inc.	07-05-1989				
	СН	GB	2,153,356	A	California Inst. Technol.	08-21-1985				
	CI	wo	88/02004	A	Applied Biosystems, Inc.	03-24-1988				
	CJ	wo	93/12132	A	CNRS (Paris)	06-24-1993			X <sup>+</sup>	

		OTHER - NON PATENT LITERATURE DOCUMENTS	***	
Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial,	Tran	slation
Initials <sup>1</sup>	No.	symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Yes	No*
	СК	BEAUCAGE et al., Tetrahedron, 49 (28), 6123-6194 (1993).		
	CL	BROWN et al., J. Chem. Soc., Chem. Commun. (Royal Society of Chemistry), 891-893 (1989).		
	СМ	CAO et al., Tetrahedron Lett., 24 (10), 1019-1020 (1983).		
	CN	GARDRAT et al., J. Heterocycl. Chem, 27, 811-812 (March-April 1990).		
	CO	GRAJKOWSKI et al., Org. Lett., 3 (9), 1287-1290 (December 2001).		
	СР	GUZAEV et al., Tetrahedron Lett., 41, 5623-5626 (2000).		
	CQ	IYER et al., J. Org. Chem., 60, 5388-5389 (1995).		-
	CR	IYER et al., Tetrahedron: Assymetry, 6 (5), 1051-1054 (1995).		
	cs	KAWANOBE et al., Chem. Lett. (Chemical Society of Japan), 825-828 (1982).		
	СТ	MIZRAKH et al., Zh. Obschei Khimii, 45 (7), 1469-1473 (July 1975).		

- A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
- + An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner Signature	Date Considered	
Oignature	Oonsidered	

<sup>&</sup>lt;sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please 1	type a	plus	sign	(+)	inside	this	box	-
----------	--------	------	------	-----	--------	------	-----	---

PTO/SB/08A/B (10-96)
ed for use through 10/31/99. OMB 0651-0031
Patent and Trad
Office: U.S. DEPARTMENT OF COMMERCE

				©/		
			PADEMARY	-	Complete if Known	
Substitute for	form 1449A/B/PTO		MADEN	Application Number	09/937,292	
INF	ORMATION	DIS	CLOSURE	Filing Date	September 24, 2001	
STA	ATEMENT BY	/ AF	PPLICANT	First Named Inventor	BEAUCAGE, Serge L.	
				Group Art Unit		
	(Use as many sheet	s as n	ecessary)	Examiner Name		
Sheet	5	of	5	Attorney Docket Number	213763	

Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Yes	No		
	CU	MIZRAKH et al., Zh. Obschei Khimii, 45 (10), 2343-2344 (October 1975).				
	CV	PUDOVIK et al., "N-Acylated Oxazaphospholanes and Phosphorinanes," Chem. Abstracts, 79 (11): 66261y (1973).				
	CW	PUDOVIK et al., "Synthesis of N-Acylated 1, 3, 2-Oxaazaphospholanes," Chem. Abstracts, 81 (11): 63723f (1974).				
	СХ	SCREMIN et al., J. Org. Chem., 59 (8), 1963-1966 (April 22, 1994).				
	CY	SMITH et al., Nucleosides & Nucleotides, 15 (10), 1581-1594 (1996)				
	CZ	STEC et al., Nucleic Acids Res., 21, 5883-5888 (November 11, 1991).				
	DA	WALDNER et al., Bioorg Med. Chem. Letters, 6 (19), 2363-2366 (1996)		******		
	DB	WANG et al., Tetrahedron Lett., 38 (22), 3797-3800 (1997).				
	DC	YANG et al., Chem. Abstracts, 111: 97382x (1989).				
	DD	ZHANG et al., Chem. Abstracts, 126 (2): 18939t (1997).				
				-		

<sup>\*</sup> A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

<sup>+</sup> An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

<sup>&</sup>lt;sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.